Tazemetostat (TAZVERIK®) is included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-cell Lymphomas with a category 2A recommendation as an option for appropriate patients with R/R FL.2
R/R=relapsed or refractory; FL=follicular lymphoma, EZH2=enhancer of zeste homolog 2.
References: 1. TAZVERIK (tazemetostat) Prescribing Information. Cambridge, MA: Epizyme, Inc., July 2020. 2. Referenced with permission
from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-cell Lymphomas V.2.2023. © National Comprehensive
Cancer Network, Inc. 2023. All rights reserved. Accessed February 8, 2023. To view the most recent and complete version of the guideline,
go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any
responsibility for their application or use in any way. 3. U.S. Food & Drug Administration (FDA). FDALabel Database. Accessed March 2,